CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Pharmaceutical Technology
Original article

Halozyme and Incyte sign licence agreement for INCA033989 formulations

PartnershipINCA033989Positive
AI Analysis

Summary

Halozyme and Incyte have signed a global partnership and licence agreement to evaluate additional subcutaneous formulations of INCA033989 in patients with mutCALR-expressing MPNs.

Importance:6/10
Sentiment:
0.50
licensing agreementpartnershipsubcutaneous formulationsmyeloproliferative neoplasms
Related Companies

Read the original article

Published by Pharmaceutical Technology on July 21, 2026 8:31 AM

Read Original